Amarin Corp Plc (AMRN)

[Bill B]

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Pradhan predicted that the same study conducted in a population of both men and women would find similar results. “Women tend to develop insulin resistance in this profile later in life, so it may have to do with the fact that we have a population of middle-aged and older women,” she said. “Residual risk is a problem that's universal: it's there for men and women and for different ethnicities, and so it's a problem for everyone.”

For now, the study is scientifically relevant and “really invokes a lot of questions about how these conditions may differ,” Pradhan said. “It also may explain why triglycerides alone as a marker of risk and targeting therapy may not explain why some of the drugs that we're currently using to treat these patients with high triglycerides seem to be unlinked with how low your triglycerides get. It may be the wrong marker for the risk/benefit that we're getting from some of the therapies that we're using.”

Once the findings are replicated in other studies, “they could be used in identifying a patient who would most benefit from some of the new therapies that we're developing,” she said. For example, TRL in particular might be helpful in explaining the biologic effects of icosapent ethyl (Vascepa; Amarin) in reducing triglycerides, Pradhan explained. “In terms of unlocking the pathways that are involved, I think they can be very useful.”

https://www.tctmd.com/news/different-markers-dyslipidemia-could-help-fine-tune-cvd-prevention